Drug Profile


Alternative Names: AB-0024; Anti-LOXL2 monoclonal antibody; GS-6624

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arresto Biosciences
  • Developer Gilead Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Chemokine CXCL12 inhibitors; Connective tissue growth factor inhibitors; LOXL2 protein-inhibitors; Transforming growth factor beta1 inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatic fibrosis; Liver cirrhosis; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis
  • Discontinued Colorectal cancer; Idiopathic pulmonary fibrosis; Myelofibrosis; Pancreatic cancer

Most Recent Events

  • 20 Apr 2017 Interim efficacy data from a phase IIb trial in Non-alcoholic steatohepatitis released by Gilead Sciences
  • 19 Apr 2017 Efficacy and safety data from phase IIb trial in Primary sclerosing cholangitis presented at The International Liver Congress 2017 (ILC-2017)
  • 19 Apr 2017 Efficacy and safety data from two phase IIb trial in Nonalcoholic steatohepatitis and Cirrhosis presented at The International Liver Congress 2017 (ILC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top